LIGAND PHARMACEUTICALS INC (LGND) Executive Compensation
LIGAND PHARMACEUTICALS INC (LGND) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: LGND
CIK: 886163
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Ernst & Young LLP
Auditor SinceSince 12/31/2016 12:00:00 AM
Lead Engagement PartnerEmma Epes
Audit LocationSan Diego, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-10-06 | 2026-10-02 | FORM 4 | 0001950232-26-000003 | View SEC Doc Filr Page |
| 4 | 2026-09-24 | 2026-09-22 | PRIMARY DOCUMENT | 0002001011-26-000142 | View SEC Doc Filr Page |
| 8-K | 2026-09-24 | 2026-09-24 | 8-K | 0000886163-26-000054 | View SEC Doc Filr Page |
| 8-K | 2026-09-22 | 2026-09-22 | 8-K | 0000886163-26-000050 | View SEC Doc Filr Page |
| 4 | 2026-09-14 | 2026-09-10 | PRIMARY DOCUMENT | 0002001011-26-000140 | View SEC Doc Filr Page |
| 144 | 2026-09-10 | — | 144 Filing | 0001950047-26-009263 | View SEC Doc Filr Page |
| 4 | 2026-09-08 | 2026-09-03 | PRIMARY DOCUMENT | 0002001011-26-000137 | View SEC Doc Filr Page |
| 144 | 2026-09-03 | — | 144 Filing | 0001950047-26-009091 | View SEC Doc Filr Page |
| 8-K/A | 2026-09-02 | 2026-07-14 | 8-K/A | 0000886163-26-000048 | View SEC Doc Filr Page |
| 4 | 2026-08-14 | 2026-08-12 | PRIMARY DOCUMENT | 0002001011-26-000115 | View SEC Doc Filr Page |
| 4 | 2026-08-14 | 2026-08-12 | PRIMARY DOCUMENT | 0002001011-26-000114 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-13 | — | SCHEDULE 13G Filing | 0000914208-26-000299 | View SEC Doc Filr Page |
| 144 | 2026-08-12 | — | 144 Filing | 0001950047-26-008026 | View SEC Doc Filr Page |
| 144 | 2026-08-12 | — | 144 Filing | 0001950047-26-008011 | View SEC Doc Filr Page |
| 10-Q | 2026-08-07 | 2026-06-30 | 10-Q | 0000886163-26-000044 | View SEC Doc Filr Page |
| 8-K | 2026-08-06 | 2026-08-06 | 8-K | 0000886163-26-000041 | View SEC Doc Filr Page |
| 4 | 2026-08-04 | 2026-08-03 | PRIMARY DOCUMENT | 0002001011-26-000111 | View SEC Doc Filr Page |
| S-8 | 2026-07-22 | — | S-8 | 0001193125-26-312502 | View SEC Doc Filr Page |
| 8-K | 2026-07-14 | 2026-07-14 | 8-K | 0001193125-26-302660 | View SEC Doc Filr Page |
| 4 | 2026-07-06 | 2026-06-30 | PRIMARY DOCUMENT | 0002001011-26-000108 | View SEC Doc Filr Page |
| 4 | 2026-07-06 | 2026-06-30 | PRIMARY DOCUMENT | 0002001011-26-000107 | View SEC Doc Filr Page |
| 4 | 2026-07-06 | 2026-06-30 | PRIMARY DOCUMENT | 0002001011-26-000106 | View SEC Doc Filr Page |
| 144 | 2026-07-01 | — | 144 Filing | 0001950047-26-006760 | View SEC Doc Filr Page |
| 8-K | 2026-06-25 | 2026-06-25 | 8-K | 0001193125-26-282990 | View SEC Doc Filr Page |
| 8-K | 2026-06-22 | 2026-06-22 | 8-K | 0001193125-26-276694 | View SEC Doc Filr Page |